News By Tag
News By Location
Global Marekts Direct: Stem Cell Therapy Market in Asia-Pacific to 2018
ENDSStem Cell Research in Asia-Pacific a “Growth Engine” for Region’s Scientific Ambitions
Stem cells are unique body cells that possess the ability to divide and differentiate into diverse cell types, and can be used to produce more stem cells. The use of adult stem cells has been successfully employed to treat bone and blood related disorders such as leukemia, through bone marrow transplants. Stem cell therapy is used to repair and regenerate the damaged tissue, though the actual mechanism of action is largely unknown.
The growth in the stem cell therapy market will not only provide treatment options but will also contribute significantly to the countries’ Gross Domestic Product (GDP), with the President of South Korea only last year referring to stem cell research as a “new growth engine” for the nation’s economy. In order to support the stem cell industry, regulatory guidelines in Asia-Pacific countries allow stem cell research, and this has led to its commercialization. India and South Korea are the leaders in the commercialization of stem cell therapy, with approved products for Acute Myocardial Infarction (AMI), osteoarthritis and anal fistula in Crohn’s disease, amongst others. The countries allow the use of human embryonic stem cells and provide adequate funding support for the research.
For Sample Pages, please click or add the below link to your browser:
Stem cell therapy is an emerging field, and a large amount of research is currently being carried out by institutions such as hospitals, universities and medical colleges. According to our analysis of the stem cell therapy research in Asia-Pacific, 63% of pipeline molecules were being researched by academia. The emergence of institutional research has boosted stem cell discoveries, as companies can be put off conducting research due to uncertain therapeutic outcomes. China and Japan witness only a negligible industry presence in stem cell research, as academic institutions dominate – however in contrast, India has the presence of both industry and academia. The major institutions engaged in stem cell research in India are LV Prasad Eye Institute (LYPEI) for Limbal Stem Cell Technology (LSCT), and the Post Graduate Institute of Medical Education and Research (PGIMER) for stem cell therapy for type 2 diabetes mellitus.
The market is poised for significant growth in the future, due to the anticipated launch of JCR Pharmaceuticals’
This report provides an in-depth analysis on stem cell research and development in India, China, Japan, South Korea and Singapore. Market analysis and forecasts are given for CABG, LSCT, Type 1 DM, Type 2 DM, Hearticellgram, Cerecellgram, Cartistem and Cupistem. The report also provides information on trends and pipelines, and covers market drivers and challenges for the stem cell research market.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by our team of industry experts.
Visit our Report Store
For more details contact: